1 / 8

Financial Conflicts of Interest in Medical Research

Financial Conflicts of Interest in Medical Research. Karen Santoro Deputy Ethics Counselor National Institute of Allergy and Infectious Diseases. Favorable Results. Inconclusive Results. Negative Results. Financial Ties to Sponsor. NEJM Vol. 338 (1998) Stelfox. Clinical Research Support.

lara-randolph
Download Presentation

Financial Conflicts of Interest in Medical Research

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Financial Conflicts of Interest in Medical Research Karen Santoro Deputy Ethics Counselor National Institute of Allergy and Infectious Diseases

  2. Favorable Results Inconclusive Results Negative Results Financial Ties to Sponsor NEJM Vol. 338 (1998) Stelfox

  3. Clinical Research Support NIH 30% 70% Industry NEJM Vol. 342 (2000) Brodenheimer

  4. Industry Support Of Academic Health Centers

  5. “Genomics and New Technologies as Catalysts for Change in the Drug Discovery Paradigm”) Jeffery Hanke, PhD. 100 Discovery Approaches Preclinical Testing (~4yr/$2-5MM Investigational New Drug Application Clinical Trials, Phase I (~1.0 year/$5-10MM) Clinical Trials, Phase II (~2.0 year/$25-50MM) Clinical Trials, Phase III (~3.0 year/$250-500MM) New Drug Application (~2.5 years) 1 Approval Figure 1. The procedure for gaining FDA approval of a pharmaceutical product based on internal benchmarks

  6. 1995 • Objectivity in Research Regulations • Disclose “significant” interests • Institution discretion

  7. Future • AAU Report Oct. 2001 • GAO Report Nov. 2001 • AAMC Task Force Dec. 2001 • AMA Recommendations Jan. 2002

More Related